Back

Atrial fibrillation/flutter may modify the long-term effect of primary prevention implantable cardioverter-defibrillators in non-ischemic HFrEF: an extended follow-up study of the DANISH trial

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Arrhythmias and devices Implantable Cardioverter-Defibrillator (ICD) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Seiko N Doi

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Implantable cardioverter-defibrillator at least as effective in frail patients with nonischemic heart failure with reduced ejection fraction: extended follow-up of the DANISH trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Impact of preventive catheter ablation on heart failure outcomes in patients with ischemic cardiomyopathy and infarct-related coronary chronic total occlusion, insights from the PREVENTIVE VT trial
Doctor M. Mrak (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
Long-term healthcare utilization and outcomes in patients hospitalized for heart failure with and without atrial fibrillation: an exploratory analysis of the PACT-HF trial
Mrs F. Verelst (Edegem, BE)
Abstract Slides Video
Presentation thumbnail
Interim analysis of the AIM-HF study: non-invasive hemodynamic monitoring in heart failure patients using radio-frequency sensing
Ms M. Wosten (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Multiparametric intravascular sensor for remote patient monitoring of heart failure
Mr I. Luque Del Toro (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias and devices
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Competing risks of ventricular tachyarrhythmias and mortality in advanced heart failure: impact of left ventricular ejection fraction
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro
thumbnail
Congress Presentation
ICD therapy is indicated for all patients with non-ischaemic cardiomyopathy and severely impaired LVEF: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources